GlassScriptPhysician profile
Roland Peter Jones
NPI 1720074610
$14,969.37
in general payments reported to CMS, 2019-2025
68 companies · $1,920 in 2025
The $1,920 reported for 2025 was more than what 79% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,772 · 2020: $2,110 · 2021: $2,207 · 2022: $2,950 · 2023: $1,933 · 2024: $2,078 · 2025: $1,920.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,931.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,930.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,973.01 | 2019-2025 | Proclaim, Eterna |
| Abbvie INC. | $1,873.49 | 2021-2025 | |
| Amgen INC. | $820.04 | 2019-2025 | Uplizna, Aimovig |
| Boston Scientific Corporation | $819.10 | 2019-2025 | Wavewriter Alpha Prime 16, Vercise, General - Dbs |
| Collegium Pharmaceutical, INC. | $749.26 | 2019-2025 | Xtampza, Belbuca |
| Nevro Corp. | $690.62 | 2019-2024 | Senza |
| Allergan, INC. | $673.17 | 2019-2022 | |
| Pfizer INC. | $649.04 | 2019-2025 | |
| Ucb, INC. | $567.97 | 2019-2025 | Zilbrysq, Briviact, Nayzilam |
| Lundbeck LLC | $481.71 | 2020-2025 | Vyepti |
| Teva Pharmaceuticals USA, INC. | $436.07 | 2019-2025 | Ajovy |
| Novartis Pharmaceuticals Corporation | $390.85 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $291.33 | 2019-2022 | |
| Lilly USA, LLC | $283.71 | 2019-2025 | Emgality, Kisunla |
| Csl Behring | $276.53 | 2022-2025 | Hizentra |
Show all 68 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roland Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.